Raisatun N. Sugiyanto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raisatun N. Sugiyanto has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Anna Jauch
Institute of Human Genetics, Heidelberg University, 69120 Heidelberg, Germany
1 shared publication- Benjamin Goeppert
Institute of Pathology, RKH Klinikum, 71640 Ludwigsburg, Germany
1 shared publication - Carsten Sticht
Core Facility Next Generation Sequencing, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
1 shared publication - Darko Castven
Department of Medicine I, University Medical Center Schleswig-Holstein – Campus Lübeck , Lübeck
1 shared publication David Ibberson
Deep Sequencing Core Facility, CellNetworks Excellence Cluster, Heidelberg University, 69120 Heidelberg, Germany
1 shared publicationEmely C. Dreher
Heidelberg University, Medical Faculty, Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 22 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (51) , eadh1442
Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer
Large-scale chromosomal aberrations are prevalent in human cancer, but their function remains poorly understood. We established chromosome-engineered hepatocellular carcinoma cell lines using CRISPR-Cas9 genome editing. A 33–mega–base pair region on chromosome 8p (chr8p) was heterozygously deleted, mimicking a frequently observed chromosomal deletion. Using this isogenic model system, we delineated the functional consequences of chr8p loss and its impact on metastatic behavior and patient survival. We found that metastasis-associated genes on chr8p act in concert to induce an aggressive and invasive phenotype characteristic for chr8p-deleted tumors. Genome-wide CRISPR-Cas9 viability screening in isogenic chr8p-deleted cells served as a powerful tool to find previously unidentified synthetic lethal targets and vulnerabilities accompanying patient-specific chromosomal alterations. Using this target identification strategy, we showed that chr8p deletion sensitizes tumor cells to targeting of the reactive oxygen sanitizing enzyme Nudix hydrolase 17. Thus, chromosomal engineering allowed for the identification of novel synthetic lethalities specific to chr8p loss of heterozygosity.
- 22 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (51) , eadh1442
Open AccessChromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer
Large-scale chromosomal aberrations are prevalent in human cancer, but their function remains poorly understood. We established chromosome-engineered hepatocellular carcinoma cell lines using CRISPR-Cas9 genome editing. A 33–mega–base pair region on chromosome 8p (chr8p) was heterozygously deleted, mimicking a frequently observed chromosomal deletion. Using this isogenic model system, we delineated the functional consequences of chr8p loss and its impact on metastatic behavior and patient survival. We found that metastasis-associated genes on chr8p act in concert to induce an aggressive and invasive phenotype characteristic for chr8p-deleted tumors. Genome-wide CRISPR-Cas9 viability screening in isogenic chr8p-deleted cells served as a powerful tool to find previously unidentified synthetic lethal targets and vulnerabilities accompanying patient-specific chromosomal alterations. Using this target identification strategy, we showed that chr8p deletion sensitizes tumor cells to targeting of the reactive oxygen sanitizing enzyme Nudix hydrolase 17. Thus, chromosomal engineering allowed for the identification of novel synthetic lethalities specific to chr8p loss of heterozygosity.